Studer, Martina; Goeggel Simonetti, Barbara; Heinks Maldonado, Theda; Steinlin, Maja; Leichtle, Alexander Benedikt; Berger, Steffen Michael; Joeris, Alexander (2015). Acute S100B in serum is associated with cognitive symptoms and memory performance 4 months after paediatric mild traumatic brain injury. Brain injury, 29(13-14), pp. 1667-1673. Informa Healthcare 10.3109/02699052.2015.1075250
|
Text
Acute S100B in Serum is associated with cognitive symptoms and memory performance four.pdf - Accepted Version Available under License Publisher holds Copyright. Download (7MB) | Preview |
OBJECTIVE
This study explored whether acute serum marker S100B is related with post-concussive symptoms (PCS) and neuropsychological performance 4 months after paediatric mild traumatic brain injury (mTBI).
RESEARCH DESIGN AND METHODS
This prospective short-term longitudinal study investigated children (aged 6-16 years) with mTBI (n = 36, 16 males) and children with orthopaedic injuries (OI, n = 27, 18 males) as a control group. S100B in serum was measured during the acute phase and was correlated with parent-rated PCS and neuropsychological performance 4 months after the injury.
MAIN OUTCOMES AND RESULTS
The results revealed no between-group difference regarding acute S100B serum concentration. In children after mTBI, group-specific significant Spearman correlations were found between S100B and post-acute cognitive PCS (r = 0.54, p = 0.001) as well as S100B and verbal memory performance (r = -0.47, p = 0.006). In children after OI, there were insignificant positive relations between S100B and post-acute somatic PCS. In addition, insignificant positive correlations were found between neuropsychological outcome and S100B in children after OI.
CONCLUSIONS
S100B was not specific for mild brain injuries and may also be elevated after OI. The group-specific association between S100B and ongoing cognitive PCS in children after mTBI should motivate to examine further the role of S100B as a diagnostic biomarker in paediatric mTBI.